Soligenix Inc SNGX

Healthcare Biotechnology

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics segment is developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Development programs in this segment also include expansion of synthetic hypericin (SGX302) into psoriasis and dusquetide (SGX942 and SGX945) for the treatment of inflammatory diseases. Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19.

NDAQ:SNGX - Post by User

Soligenix Inc

Bullboard Posts

Next >>

Post by borrockon Nov 25, 2020 2:30pm

823 Views

Post# 31971454

Future trend

ZACKS SCR IS BULLISH ON SOLIGENIX, SUGGESTING 580% UPSIDE; MULTIPLE ASSETS COMBINE TO SET UP THREE NEAR-TERM POTENTIAL CATALYSTS

Soligenix (NASDAQ: SNGX) is earning Zacks SCR analysts’ confidence, who prescribe a 12-month price target of $15 per share. A rise in that magnitude represents a more than 580% increase from its current trading price*. Several reasons combine to justify the lofty valuation. (*share price and percentage calculation as of 11:00ET 11/23/20)